Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.

Pamuk ON, Tsokos GC.

Arthritis Res Ther. 2010;12(6):222. doi: 10.1186/ar3198. Epub 2010 Dec 17. Review.

2.

PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

Reilly MP, Sinha U, André P, Taylor SM, Pak Y, Deguzman FR, Nanda N, Pandey A, Stolla M, Bergmeier W, McKenzie SE.

Blood. 2011 Feb 17;117(7):2241-6. doi: 10.1182/blood-2010-03-274969. Epub 2010 Nov 18.

3.

The SYK tyrosine kinase: a crucial player in diverse biological functions.

Mócsai A, Ruland J, Tybulewicz VL.

Nat Rev Immunol. 2010 Jun;10(6):387-402. doi: 10.1038/nri2765. Review.

4.

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE Jr, Green LA, Hochman JS, Jacobs AK, Krumholz HM, Morrison DA, Ornato JP, Pearle DL, Peterson ED, Sloan MA, Whitlow PL, Williams DO; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Circulation. 2009 Dec 1;120(22):2271-306. doi: 10.1161/CIRCULATIONAHA.109.192663. Epub 2009 Nov 18. No abstract available. Erratum in: Circulation. 2010 Mar 30;121(12):e257. Dosage error in article text.

5.

The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.

Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble JA, Watson SP.

J Thromb Haemost. 2009 Jul;7(7):1192-9. doi: 10.1111/j.1538-7836.2009.03451.x. Epub 2009 Apr 24.

6.

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O'Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Circulation. 2009 Jan 27;119(3):e21-181. doi: 10.1161/CIRCULATIONAHA.108.191261. Epub 2008 Dec 15. No abstract available. Erratum in: Circulation. 2011 Oct 18;124(16):e424. Circulation. 2010 Jul 6;122(1):e11. Circulation. 2009 Jan 27;119(3):e182.

7.

Evaluation of the physiological significance of botrocetin/ von Willebrand factor in vitro signaling.

Liu J, Joglekar M, Ware J, Fitzgerald ME, Lowell CA, Berndt MC, Gartner TK.

J Thromb Haemost. 2008 Nov;6(11):1915-22. doi: 10.1111/j.1538-7836.2008.03135.x. Epub 2008 Aug 22.

8.

Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress.

Speich HE, Grgurevich S, Kueter TJ, Earhart AD, Slack SM, Jennings LK.

Am J Physiol Cell Physiol. 2008 Oct;295(4):C1045-54. doi: 10.1152/ajpcell.90644.2007. Epub 2008 Aug 20.

9.

Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.

Karnicki K, Leadley RJ Jr, Baxi S, Peterson T, Wysokinski W, McBane RD 2nd.

Thromb Haemost. 2008 Apr;99(4):759-66. doi: 10.1160/TH07-09-0576.

PMID:
18392334
10.

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Halperin JL, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine.

Circulation. 2007 Aug 14;116(7):e148-304. Epub 2007 Aug 6. No abstract available. Erratum in: Circulation. 2008 Mar 4;117(9):e180.

11.

Spleen tyrosine kinase participates in Src-mediated migration and proliferation by PDGF-BB in rat aortic smooth muscle cells.

Lee HM, Kim HJ, Park HJ, Won KJ, Kim J, Shin HS, Park PJ, Kim HJ, Lee KY, Park SH, Lee CK, Kim B.

Arch Pharm Res. 2007 Jun;30(6):761-9.

PMID:
17679556
12.

In vivo thrombus formation in murine models.

Sachs UJ, Nieswandt B.

Circ Res. 2007 Apr 13;100(7):979-91. Review.

13.

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES.

J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. Epub 2006 Aug 31. Erratum in: J Pharmacol Exp Ther. 2013 May;345(2):326.

14.

Adverse impact of bleeding on prognosis in patients with acute coronary syndromes.

Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S.

Circulation. 2006 Aug 22;114(8):774-82. Epub 2006 Aug 14.

15.

Lipid raft adhesion receptors and Syk regulate selectin-dependent rolling under flow conditions.

Abbal C, Lambelet M, Bertaggia D, Gerbex C, Martinez M, Arcaro A, Schapira M, Spertini O.

Blood. 2006 Nov 15;108(10):3352-9. Epub 2006 Jul 18.

16.

Pathological shear stress directly regulates platelet alphaIIbbeta3 signaling.

Feng S, Lu X, Reséndiz JC, Kroll MH.

Am J Physiol Cell Physiol. 2006 Dec;291(6):C1346-54. Epub 2006 Jul 5.

17.

Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo.

Dubois C, Panicot-Dubois L, Merrill-Skoloff G, Furie B, Furie BC.

Blood. 2006 May 15;107(10):3902-6. Epub 2006 Feb 2.

18.

Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRgamma deficiency.

Mangin P, Yap CL, Nonne C, Sturgeon SA, Goncalves I, Yuan Y, Schoenwaelder SM, Wright CE, Lanza F, Jackson SP.

Blood. 2006 Jun 1;107(11):4346-53. Epub 2006 Jan 3.

19.
20.

Leukocyte engagement of platelet glycoprotein Ibalpha via the integrin Mac-1 is critical for the biological response to vascular injury.

Wang Y, Sakuma M, Chen Z, Ustinov V, Shi C, Croce K, Zago AC, Lopez J, Andre P, Plow E, Simon DI.

Circulation. 2005 Nov 8;112(19):2993-3000. Epub 2005 Oct 31.

Supplemental Content

Support Center